T2 Biosystems (TTOO) said Monday it was starting a multi-year distribution agreement with Cardinal Health (CAH), which will exclusively sell its direct-from-blood diagnostics equipment for the rapid detection of sepsis-causing pathogens.
Among the devices included under the new agreements are T2 Biosystems' US Food and Drug Administration-authorized T2Dx Instrument, T2Bacteria Panel and the T2Candida Panel. Financial terms and other details of the new contract were not disclosed.
Price: 111.65, Change: -0.34, Percent Change: -0.30
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。